AA
RANI icon

AlphaMark Advisors’s Rani Therapeutics RANI Stock Holding History

AlphaMark Advisors’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$1K Buy
+500
New +$1.05K ﹤0.01% 598

Other funds holding RANI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

AlphaMark Advisors's RANI Position: Q4 2024 in Review

AlphaMark Advisors opened a new position in Rani Therapeutics (RANI) in Q4 2024: 500 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #598 among its holdings.

42 funds tracked by Wall St. Rank hold RANI as of Q4 2024.

  • AlphaMark Advisors held 500 shares of Rani Therapeutics worth $1K as of Q4 2024.
  • Rani Therapeutics was a new AlphaMark Advisors position in Q4 2024.
  • Rani Therapeutics made up ﹤0.01% of AlphaMark Advisors's portfolio in Q4 2024, its #598 holding.
  • 42 funds tracked by Wall St. Rank held Rani Therapeutics as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.